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Abstract
Trivalent inactivated vaccines (TIV) against influenza are given to 350 million people every year. Most of these are non-
adjuvanted vaccines whose immunogenicity and protective efficacy are considered suboptimal. Commercially available
non-adjuvanted TIV are known to elicit mainly a humoral immune response, whereas the induction of cell-mediated
immune responses is negligible. Recently, a cationic liposomal adjuvant (dimethyldioctadecylammonium/trehalose 6,69-
dibehenate, CAF01) was developed. CAF01 has proven to enhance both humoral and cell-mediated immune responses to a
number of different experimental vaccine candidates. In this study, we compared the immune responses in ferrets to a
commercially available TIV with the responses to the same vaccine mixed with the CAF01 adjuvant. Two recently circulating
H1N1 viruses were used as challenge to test the vaccine efficacy. CAF01 improved the immunogenicity of the vaccine, with
increased influenza-specific IgA and IgG levels. Additionally, CAF01 promoted cellular-mediated immunity as indicated by
interferon-gamma expressing lymphocytes, measured by flow cytometry. CAF01 also enhanced the protection conferred by
the vaccine by reducing the viral load measured in nasal washes by RT-PCR. Finally, CAF01 allowed for dose-reduction and
led to higher levels of protection compared to TIV adjuvanted with a squalene emulsion. The data obtained in this human-
relevant challenge model supports the potential of CAF01 in future influenza vaccines.
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Introduction
Efforts to prevent or minimize the impact of seasonal influenza
in the second part of the 20th century have focused on the use of
vaccines [1]. Due to the yearly changes in viral antigenic
configuration [2] and the lack of carry-over protection from year
to year [3], vaccination campaigns annually require a huge logistic
effort to ensure that the production and delivery of the seasonal
vaccine is sufficient for high population coverage [4]. In addition,
the time span between the selection of the vaccine strains to the
vaccine being commercially available is between 6 and 8 months
[5]. In the case of pandemic avian influenza, the world population
would be considered immunologically naı¨ve, which would imply
that a large part of the population should be vaccinated twice [6].
Given the current production capacities and limitations, such a
demand could not be fulfilled on time, and even a single
vaccination world-wide would not be realistic [7]. Additionally,
the protection provided by current non-adjuvanted influenza
vaccines is short-lived and declines after six months. This means
that such a vaccine most likely would not be able to protect
individuals against the second wave of flu sometimes observed in
pandemics [8]. Also, the quality of the immune response conferred
by the available killed virus vaccines has been debated and is
almost solely focused on a humoral response directed against
highly variable surface proteins [9], whereas the induction of cell-
mediated immune (CMI) responses is negligible [10,11]. In
contrast, it has been shown during natural infections that T-cells
target primarily conserved proteins from the inner part of the
virion that may mediate cross-protection against heterologous
strains [12] and long-lived protection [13]. Protection relying
solely on antibodies, as induced by the most common inactivated
vaccines, is short-lived and falls below effective levels after 6 to 12
months, especially in the elderly. Therefore, the ideal vaccine to
fight both epidemic and pandemic influenza should induce both a
humoral and a cellular immune response with only one injection
of a minimal dose [14].
Several strategies have been considered to remediate the
shortcomings of non-adjuvanted influenza vaccines. Live-attenu-
ated vaccines (LAIV) for intra-nasal immunization have been
commonly used in some parts of Europe, and FluMist became in
2003 the first LAIV available outside of Europe. However, LAIV
are not recommended for children under 2 or adults over 50,
which are the two populations the most at risk for severe influenza.
Other mucosal routes of immunization, such as oral [15] or
sublingual [16], have also been considered, but the few vaccines
that have reached the market are still treated with caution [17].
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Mucosal tolerance remains a hurdle when it comes to designing
new mucosal vaccines not relying on live vectors. The addition of
an adjuvant to the TIV to improve its immunogenicity is another
favoured strategy. A recent study showed high antibody titers after
injection of an aluminium-adjuvanted vaccine [18]; however this
type of adjuvant (reviewed in [19]) has shown little or no benefits
in most other studies [20,21]. Although it is the only adjuvant
available for world-wide usage in humans, it is generally accepted
that novel and more effective adjuvants should be employed for
influenza vaccines. Water-in-oil emulsion adjuvants have been
widely used in experimental and commercial influenza vaccines,
with MF59 being the first emulsion licensed for human use in
some European countries. A number of other oil-in-water
emulsions are currently in the pipeline for both pandemic and
pre-pandemic influenza vaccines, and GlaxoSmithKline recently
developed a pandemic and a pre-pandemic avian influenza
vaccine, both using the oil-in-water emulsion AS03, and both
being approved in Europe since May 2008 [22]. However, this
adjuvant may not be the most efficient way of inducing strong Th1
responses and alternative vaccination strategies, e.g. the use of
other CMI-inducing adjuvants or combination adjuvants supple-
menting emulsions with immunomodulators like CpG or MPL
[23], remain therefore a highly prioritized research area.
In this study, the effect of a novel combination adjuvant,
cationic adjuvant formulation 01 (CAF01), in a conventional TIV
against influenza was investigated. This new adjuvant based on
cationic dimethyldioctadecylammonium (DDA) and trehalose
6,69-dibehenate (TDB) induces both a strong T-cell response
and a concomitant antibody response. Similar promising results
for CAF01 have been described in other models, including
malaria, chlamydia and tuberculosis [24,25]. The studies present-
ed here were performed using ferrets for testing both immunoge-
nicity and protection.
Although considered the preferred animal model for use within
the field of influenza, the lack of ferret-specific reagents has limited
the use of relevant in vitro assays. Herein, we used the recently
developed panel of reagents including antibodies against, Immu-
noglobulin subclasses, cytokines and T cell subsets [26] for
monitoring immune response induced by a CAF01-adjuvanted
influenza vaccine. The adjuvant was found to increase the levels of
IgG and IgA antibodies to influenza proteins in nasal washes and
serum, and the functionality of those antibodies was confirmed by
a hemagglutination inhibition assay. In addition, intracellular
staining of interferon-gamma (IFN-c) demonstrated the induction
of T-cell responses upon vaccination and subsequent influenza
challenge. Along with the highly elevated immune responses,
CAF01 led to a significantly accelerated reduction in the viral load
compared to the un-adjuvanted split vaccine, even when using a
low dose of 0.15 mg split vaccine. CAF01 also produced higher
IgG titers and led to a lower shedding of viral particles in infected
animals compared to an emulsified squalene adjuvant.
Materials and Methods
Ethics statement
All experiments were approved by the Danish Animal Care and
Ethics Committee and conducted in accordance with the Danish
Animal Experimentation Act and the European Convention for
the Protection of Vertebrate Animals used for Experimental and
Other Scientific Purposes (permit nr 2006/561–1105).
Vaccine and adjuvant
The CAF01 adjuvant was used in a dosage of 1250 mg DDA
and 250 mg TDB from Avanti Polar Lipids (Alabaster, AL)
prepared as previously described [25]. The squalene emulsion was
used in a dosage of 4.85 mg DL-a-tocopherol , 11.86 mg
Polysorbat 80 and 10.68 mg squalene from Sigma-Aldrich
(Steinheim, Germany) as previously described for the adjuvant
in the Prepandrix vaccine [27]. The formulation was emulsified
using a IKA T25 digital ULTRA-TURRAXH high shear mixer
(Staufen, Germany) under 6,000 rpm for 5 minutes in order to
provide a homogeneous feedstock for final emulsification [28].
The final squalene emulsion was generated by ten serial passages
of emulsion through a polycarbonate membrane from Avestin
(Mannheim, Germany) with a pore diameter of 200 nm. Sanofi-
Pasteur’s Vaxigrip TIV was purchased from a commercial
distributor. The two vaccines used in this study were the 2005/
2006 formulation containing 15 mg of hemagglutinin (HA) from
A/New Caledonia/20/99 (H1N1), 15 mg of HA from A/New
York/55/2004 (H3N2) and 15 mg of HA from B/Jiangsu/10/
2003; and the 2008/2009 formulation containing 15 mg of HA
from A/Brisbane/59/2007 (H1N1), 15 mg of HA from A/
Brisbane/10/2007 (H3N2) and 15 mg of HA from B/Florida/4/
2006.
Immunization schedule
All experiments were performed on outbred, 6 to 10 months
old, female ferrets (Mustela putorius furo) obtained from Møldrup fur
farm (Møldrup, Denmark). The ferrets were housed in a class II
isolation facility at the Faculty of Life Sciences, University of
Copenhagen, with free access to food and water. Prior to
vaccinations, animals were confirmed to be seronegative for
circulating influenza A (H1N1 and H3N2) and influenza B viruses
by haemagglutination inhibition assay (HAI) and ELISA. For the
A/New Caledonia/20/99 (H1N1) challenge study, ferrets (n = 8)
were immunized intra-muscularly (i.m.) in the hind leg with
CAF01 (250 ml) adjuvanted or non-adjuvanted Vaxigrip (80 ml,
containing 2.5 mg of each HA) twice at week 0 and 2 weeks after.
A control group of unvaccinated animals received 250 ml of PBS
per injection instead of the vaccine. 6 weeks after vaccination, all
animals were inoculated intranasally (i.n.) with 107 TCID50 of A/
New Caledonia/20/99 (H1N1) produced in eggs. This study was
performed three times with the same design. For the A/Brisbane/
59/2007 (H1N1) dose-response experiment, ferrets (n = 4) were
immunized twice i.m. at week 0 and week 2 with one of three
doses (0.5 ml of vaccine/15 mg of each HA, 50 ml of vaccine/
1.5 mg of each HA, or 5 ml of vaccine/0.15 mg of H1) with or
without the CAF01 adjuvant (250 ml). A control group received
only PBS. At week 6, all animals were inoculated i.n. with 107
TCID50 of A/Brisbane/59/2007 (H1N1) produced in eggs.
During challenge, in both studies, nasal washes were taken daily
from day 0 to day 6 post infection (p.i.). Blood samples were taken
from the cranial vena cava at day 3, 5, 7 and 10 p.i. For the
squalene emulsion vs CAF01 head-to-head comparison, ferrets
were immunized twice i.m in the hind leg at week 0 and week 4
with 0.5 ml of TIV with CAF01, a squalene emulsion, or without
adjuvant. A control group of mock-vaccinated animals received
only PBS. At week 6, all animals were inoculated i.n. with 107
TCID50 of A/Brisbane/59/2007 (H1N1) produced in eggs.
Viral excretion in nasal washes
Nasal washes were performed using a pipette by application of
1 ml of PBS into the nostrils of each ferret. Subsequently, the
animals sneezed and the expelled material (nasal wash sample) was
collected and kept at 280uC.
The concentration of viral RNA was measured by real time RT-
PCR using primers and probe from the matrix gene (available on
request). RNA was extracted from the samples using the total
CAF01 and Influenza Vaccine
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nucleic acid kit on the semi automatic Magnapure extraction
machine from Roche (Hvidovre, Denmark). The eluted RNA was
analyzed in one-step RT-PCR using the RT-PCR One-step kit
from Qiagen (Copenhagen, Denmark). The real-time PCR assays
were performed on an MX3005 thermocycler from Stratagene
(LaJolla, CA). For every assay, a standard curve with titrated A/
New Caledonia/99 (H1N1) or A/Brisbane/59/2007 (H1N1)
influenza virus was used to calculate the relative amount of viral
RNA present in the sample.
Influenza-specific IgG and IgA ELISA
For IgG titration, Maxisorp plates (NUNC, Roskilde, Denmark)
were coated at 4uC overnight with Vaxigrip (1 mg hemagglutinin
from H1N1 per ml) in carbonate buffer pH 9.6. The plates were
washed three times with PBS containing 0.05% Tween-20 and
blocked with PBS with 1% BSA for two hours. The plates were
washed and 100 ml of serial dilutions of serum sample were tested
in duplicates. After a one hour incubation period followed by
washes, 150 ml of biotinylated polyclonal rabbit anti-mink IgG
antibody [26] diluted 1:500 was added and the plates were
incubated for one hour. After thorough washes, 100 ml of HRP-
streptavidin (Dako, Denmark) was added followed by incubation
for 30 minutes at room temperature and subsequent development
of the reaction with OPD tablets (1,2-phenylendiamin-dihydro-
chlorid, Dako, Denmark) following the manufacturer’s instruc-
tions. IgA levels in nasal washes were investigated in a similar
fashion as for the above mentioned IgG ELISA, except that a
HRP-conjugated anti dog IgA (AbD-Serotec, Denmark) polyclon-
al antibody was used instead of the anti-IgG [26]. Antibody titers
are expressed as the highest dilution with an optical density (OD)
reading greater than 2 times the mean OD + standard deviation of
similarly diluted negative control samples.
FACS analysis of peripheral blood leucocytes
Staining was performed as previously described [29] with the
following modifications. Approximately 2 million peripheral blood
leucocytes (PBLs) prepared after hypotonic lysis of erythrocytes
with 0.15 M NH4Cl were cultured in 1 ml of modified RPMI
containing 20 mM Hepes and L-Glutamine (Sigma, St. Louis,
USA) 10% FCS (fetal calf serum), 100 IU/mL penicillin and
100 mg/mL streptomycin. For non-specific stimulation of lym-
phocytes, the cultures were incubated for 4 hours with a medium
containing brefeldin A (Sigma, St. Louis, USA) to a final
concentration of 10 mg/ml culture, ionomycin (Sigma, St. Louis,
USA) to a final concentration of 1 mg/ml and phorbol-12-
myristate-13-acetate (PMA, Sigma, St. Louis, USA) to a final
concentration of 20 ng/ml. For the antigen-specific stimulation,
the PBLs were cultured 24 hours with medium containing 1 mg/
ml of recombinant H1 hemagglutinin from A/New Caledonia/
20/99 (Protein Sciences Corporation, CT, USA). After culture,
the PBLs were fixed in 4% paraformaldehyde and permeabilized
with 0.1% saponin (Sigma, St. Louis, USA) and stained with 15 ml
of PE-conjugated ferret cross-reactive mouse monoclonal antibody
to bovine IFN-c (clone CC302, AbD-Serotec, Denmark) [26].
Finally, the cells were analyzed with a Becton Dickinson Calibur
flow cytometer. Gating for lymphocyte populations was done as
previously described [30].
Hemagglutination inhibition (HAI) assay
Hemagglutination inhibition assay was performed according to
the standard WHO protocol WHO/CDS/CSR/NCS 2002.5
Rev.1 [31]. Hemagglutination was measured by the viral
agglutination of 0.4% (vol/vol) guinea pig red blood cells (Statens
Serum Institut, Denmark). Serum samples were incubated
overnight at 37uC with 4 parts receptor destroying enzyme
(RDE) to destroy nonspecific inhibitors of hemagglutination. The
reaction was stopped by denaturing the enzyme at 56uC for
30 minutes. RDE-treated sera were two-fold serially diluted in 96-
well v-bottomed microtiter plates (Nunc, Roskilde, Denmark), and
an equal volume of virus adjusted to 8 hemagglutination units was
added. HAI titers were determined by the reciprocal dilution of
the last well which contained non-agglutinated red blood cells.
Statistical analysis data
HAI and ELISA data are given as geometric mean titer (GMT)
with 95% confidence interval. FACS and RT-PCR data are given
as arithmetic mean6 SEM. Statistical significance was asserted by
a two-way analysis of variance (ANOVA) followed by Bonferroni’s
t-test, except for the dose-reduction experiment, where a one-way
analysis of variance (ANOVA) was applied, followed by Dunnett’s
t-test. All tests were performed on log-transformed data, using
GraphPad Prism version 5.0 (La Jolla, CA). The following
conventions were used: *p,0.05, ** p,0.01, *** p,0.001.
Results
CAF01 enhances both antibody and CMI responses of the
TIV
Prior to vaccination, all ferrets were tested negative for influenza
vaccine-specific IgG antibodies in serum by ELISA, and their
baseline virus hemagglutination inhibition capacity was assessed.
Ferrets were vaccinated twice with a dose of TIV corresponding to
2.5 mg of hemagglutinin (H1) administered without adjuvant or
with CAF01. A third group was left unvaccinated. Two weeks after
the first immunization, both the groups that received the non-
adjuvanted vaccine and the vaccine with CAF01 showed a
significant increase in their vaccine-specific IgG antibody titers in
serum (fig. 1A). However, immunization with CAF01 led to higher
levels of antibody titers compared to the levels induced by the
vaccine alone (p,0.001). These increased antibody titers persisted
until week 8 with IgG antibody levels in the CAF01 group being
40-fold higher than the levels in the group receiving the vaccine
only. To further analyze the functionality of the antibody
responses, hemagglutinin inhibition assay was performed in
parallel. As shown in figure 1B, the CAF01 group also showed a
rise in HAI titers two weeks after the first immunization, whereas
no significant increase was induced by the vaccine alone at that
time point. Significant HI titers were not detected in the non-
adjuvanted group until week 8 and were about 10 times lower than
in the CAF01 group.
In order to analyse CMI responses, peripheral blood leukocytes
were isolated from the blood of immunized ferrets, cultivated for
24 hours with a recombinant H1 hemagglutinin from H1N1 A/
New Caledonia/20/99 and stained for intra-cellular IFN-c. The
percentage of IFN-c-positive lymphocytes of the total number of
lymphocytes was measured by flow cytometry at different time
points after vaccination. The baseline of about 0.5% of IFN-c
positive lymphocytes observed in naive animals remained the same
for all three groups (mock-vaccinated, vaccine only, vaccine
adjuvanted with CAF01) until week 4 after vaccination. At week 8,
the group that received CAF01 showed a significant increase in the
percentage of IFN-c positive lymphocytes reaching levels of
approximately 1.5% positive cells (fig. 1C).
CAF01-adjuvanted TIV leads to accelerated virus
clearance
Four weeks after the second immunization, ferrets received a
H1N1 challenge through the nasal cavities. Nasal washes were
CAF01 and Influenza Vaccine
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performed on infected ferrets during the first five days of the
challenge, and the relative amounts of viral RNA in each wash
were measured by quantitative RT-PCR. As shown in fig. 2A, the
group that received the vaccine adjuvanted with CAF01 showed
RNA concentrations 10 to 100-fold lower than the group that
received the vaccine only and the mock-vaccinated group. By
measuring the percentage of animals excreting virus during
infection (cumulative results of three experiments) the CAF01-
vaccinated animals were found to have 10–50 times less viral load
throughout the experiment and to clear the infection more rapidly
than the non-adjuvanted vaccine group and the control group
(fig. 2A). In contrast to the CAF01 group the mock-vaccinated
animals and animals receiving vaccine alone were found to still
excrete the virus at day 5.
To examine the protective immune responses during the
influenza infection, ferret sera and nasal fluids were examined
for antibody responses at different time points during the infection.
As previously, the quantities of antibodies against influenza
proteins in serum (IgG) and nasal washes (IgA) were measured
by ELISA whereas the HAI was performed on serum only. As
shown in figure 2B, the high titers of IgG antibodies induced by
the vaccine with the adjuvant after the second immunization
persisted during the challenge. Titers were significantly higher as
the animals entered the infection (day 0) and remained higher at
day 10 (P,0.001) in the group that received the adjuvanted
vaccine compared to the group without CAF01. Low but
significant titers of IgA antibodies in the nasal wash were detected
at the day of inoculation in the ferrets vaccinated with CAF01 and
those titers rose exponentially upon challenge (fig. 2C). In contrast,
no detectable levels of IgA were found at day 0 in the group that
received the vaccine only. In these ferrets, increasing but still very
low levels of IgA were found throughout the 10 days of challenge
with a level comparable to that of mock-vaccinated animals.
Finally, HAI titers were also higher in ferrets receiving the vaccine
adjuvanted with CAF01. The HAI titers were approximately 10
fold higher compared to the non-adjuvanted vaccine at day 0 after
challenge inoculation, and 3 times higher at day 10 (fig. 2D).
Interestingly, mock-vaccinated animals failed to show any
elevation in their HAI titers during the 10 days of the challenge.
Along with the vaccine-induced immune response, we also
measured the overall level of infection driven T cell activation
[32], by stimulating the T cells with a polyclonal activator known
to expand preferentially activated T cells (PMA and ionomycin) in
a TCR-independent manner [33,34]. The cells were subsequently
stained for intra-cellular IFN-c (fig. 2E). We used this read-out as a
marker of infection. All three groups had the same baseline levels
at day 0 and 3 p.i. (around 6% of IFN-c-positive lymphocytes) but
subsequently increased their level of intra-cellular IFN-c at day 7
after challenge in mock-vaccinated animals and animals that
received the vaccine alone. These two groups showed significantly
higher levels of IFN-c producing cells than the group that received
the vaccine adjuvanted with CAF01 indicating a better control
with viral replication and less T cell activation.
The use of CAF01 in the influenza vaccine has a clear
dose-sparing effect
In order to evaluate the dose-sparing effect of CAF01, groups of
ferrets (n = 4) received three different doses of a TIV (season 2008–
2009) corresponding to 15 mg, 1.5 mg or 0.15 mg, respectively, of
hemagglutinin from A/Brisbane/59/2007 (H1N1). The humoral
response was subsequently measured two weeks after a single
vaccination (fig. 3 A,B and C) or four weeks after a booster
vaccination (fig. 3D, E and F). After a single immunization, all
three groups that received the vaccine with CAF01 displayed
noticeable levels of antibodies measured as both IgG and HAI
titers. In these groups, antibody levels were higher than in the
groups that received the vaccine alone. This trend was
Figure 1. Vaccine-specific immune responses. 6 to 10 months-old
ferrets were immunized twice at two week-intervals with CAF01
adjuvanted (m) and non-adjuvanted (&) influenza vaccine Sanofi-
Pasteur’s Vaxigrip season 2005/2006 (n = 8 per group). A third group
was mock-vaccinated (N). A. Serum IgG antibodies against the vaccine
antigens measured by IgG specific ELISA at various timepoints. The titer
was defined as the reciprocal value of the highest positive dilution. B.
Hemagglutination inhibition assay using influenza A (New Caledonia
1999 (H1N1). HI titers were determined by the reciprocal dilution of the
last well which contained non-agglutinated red blood cells. All ELISA
values are expressed as geometric mean titers (GMT). C. Percentage of
IFN-c-positive lymphocytes: peripheral blood leucocytes were isolated
and stimulated overnight with a recombinant H1 hemagglutinin from
A/New Caledonia/20/99 (H1N1). Values marked with an asterisk are
significantly different (*, p,0.05; **, p,0.01; ***, p,0.001), assessed by
ANOVA.
doi:10.1371/journal.pone.0022891.g001
CAF01 and Influenza Vaccine
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accentuated after a booster vaccination with the three groups that
received CAF01 showing significantly higher levels than the
groups that received the vaccine alone. After both the single
immunization and the booster did even the lowest dose of vaccine
(0.15 mg) adjuvanted with CAF01 give rise to higher IgG titers
than the highest dose (15 mg) of the non-adjuvanted vaccine.
Although the levels of IgA in nasal washes were generally lower,
the group receiving CAF01-adjuvanted vaccine again displayed
levels significantly higher than their counterparts that received the
vaccine alone (fig. 3C and F).
Four weeks after the second immunization, the animals received
a H1N1 challenge through the nasal cavities. Nasal washes were
performed at day 4 post-challenge and the relative amounts of
viral RNA in each wash were measured by quantitative RT-PCR
(fig. 4A, B and C). At all three dose levels, the CAF01-adjuvanted
vaccine was the best-performing vaccine, giving rise to significantly
Figure 2. Challenge with A/New Caledonia/20/99 (H1N1). 6 to 10 months-old ferrets were immunized twice at two week- intervals with CAF01
adjuvanted (m) and non-adjuvanted (&) influenza vaccine Sanofi-Pasteur’s Vaxigrip season 2005/2006 (n = 8 per group). A third group was mock-
vaccinated (N). All ferrets were challenged with 107 TCID50 of A/New Caledonia/20/99 (H1N1) four weeks after the second immunization (n = 8 per
group). A. Relative amounts of viral RNA found in nasal washes of infected animals during the first six days of challenge, measured by quantitative RT-
PCR. B. Vaccine-specific IgG titers measured in serum by ELISA C. Vaccine-specific IgA titers measured in nasal washes by ELISA. D. Hemagglutination
inhibition assay titers using influenza A New Caledonia 1999 (H1N1). All ELISA values are expressed as geometric mean titers (GMT). E. Percentage of
IFN-c-positive lymphocytes after 4 hours stimulation with PMA and ionomycin. Values marked with an asterisk are significantly different (*, p,0.05;
**, p,0.01; ***, p,0.001), assessed by ANOVA, except for B assessed by log-rank test.
doi:10.1371/journal.pone.0022891.g002
CAF01 and Influenza Vaccine
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ower levels of virus excretion even at a low dose of 0.15 mg of
vaccine. At this dose level (0.15 mg adjuvanted with CAF01), the
reduction in viral RNA load was comparable to that observed with
the non-adjuvanted 15 mg dose. The highest level of protection
was obtained with 15 mg of vaccine in CAF01 which led to a 100-
fold reduction of the viral load compared to the same dose of
vaccine without CAF01 (fig. 4C). Finally, HAI titers were
measured in serum samples during infection and further supported
that CAF01 enhanced the effect of the TIV with all three dose
levels giving rise to significantly higher HAI titers compared to the
mock-vaccinated animals (fig. 4D, E and F).
CAF01 compares favourably to a squalene emulsion
based adjuvant
Since squalene emulsions are being increasingly used as
adjuvants for influenza vaccines, we have compared the effects
on CAF01 to that of a custom-made squalene emulsion with a
composition based on available information from the adjuvanted
prepandrix vaccine [27]. Ferrets received two injections of TIV
(15 mg of HA per dose) either without adjuvant, adjuvanted with
CAF01, or adjuvanted with the squalene emulsion. A mock-
vaccinated control group received only PBS injections. Four weeks
after the first injection, animals which received the vaccine
Figure 3. Immune responses after immunizations with different doses. 6 to 10 months-old ferrets were immunized twice at two week-
intervals with different doses of CAF01 adjuvanted and non-adjuvanted influenza vaccine Vaxigrip season 2008/2009 (n = 4 per group). White bars:
CAF01-adjuvanted vaccine, black bar: non-adjuvanted vaccine. A, B and C show results after 1 immunization. D, E and F show results after 2
immunizations. A and D show vaccine-specific IgG titers measured in serum by ELISA. B and E show hemagglutination inhibition assay serum titers
using influenza A/Brisbane/59/2007 (H1N1). C and F show vaccine-specific IgA titers measured in nasal washes by ELISA. All ELISA values are
expressed as geometric mean titers (GMT) and values marked with an asterisk are significantly different (*, p,0.05; **, p,0.01; ***, p,0.001), assessed
by ANOVA.
doi:10.1371/journal.pone.0022891.g003
CAF01 and Influenza Vaccine
PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e22891
adjuvanted with the squalene emulsion had higher vaccine-specific
serum IgG titers than the animals which received the vaccine
alone (fig. 5). At the same timepoint, the animals that received the
vaccine adjuvanted with CAF01 had antibody titers higher than
the squalene emulsion group (p,0.01). These trends were
confirmed after the second injection with animals that received
CAF01 displaying significantly higher titers of serum IgG than
those which received squalene emulsion-adjuvanted TIV or TIV
without adjuvant.
Four weeks after the second injection, the animals were
challenged intra-nasally with a homologuous influenza virus.
Nasal samples taken during the peak replication of the virus (day
4–5) showed that the squalene emulsion reduced the excretion of
viral RNA by 60 to 75% (p,0.01) compared to animals that did
not receive any vaccine, and by more than 50% compared to the
animals that received the TIV without adjuvant (fig. 5C).
Importantly, animals that received the TIV adjuvanted with
CAF01 had very low levels (close to the detection level) of viral
RNA in their nasal washes compared to control animals.
Discussion
This study demonstrates that the novel liposomal adjuvant
CAF01 potentiates the humoral response and adds an additional
CMI response to the response promoted by a commercially
available split vaccine. This adjuvantation of the vaccine results in
accelerated clearance and influenza virus titers in the nasal cavities
of ferrets were reduced by two to three orders of magnitude
compared to non-vaccinated animals.
Influenza A virus infections in mammals are characterized by a
very prompt immune response that can clear the virus 5 to 7 days
after infection [35]. Unlike many other infections, antibody
response is detectable already within the first week after infection,
noticeably with the presence of IgM in the blood and IgA in the
nasal mucus [36]. In spite of the limitations of a response based on
only humoral immunity, antibodies are still the main response
induced by influenza vaccines [9]. The CAF01 adjuvant
potentiates the production of antibodies even after a single
immunization and both in terms of serum IgG and mucosal IgA
antibodies. CAF01 induces a quantitatively larger humoral
immune response than the conventional vaccine alone and also
promote a much stronger potentiation of the response than a
squalene emulsion adjuvanted vaccine. In addition to increasing
the antibody response, CAF01 also affects the CMI response
whereas no such response was seen in ferrets receiving non-
adjuvanted split vaccine. A major improvement to the current
influenza vaccines would be an vaccine with the ability to promote
a T-cell response that could potentially lead to cross-protection
between heterologous strains [37]. Although such a cross-
protection most likely would operate more efficiently through T-
cell responses directed against conserved proteins located in the
inner part of the virion rather than the highly variable surface
proteins hemagglutinin and neuraminidase present in the vaccine
used herein, the induction of IFN-c positive lymphocytes upon
specific stimulation with recombinant H1 demonstrates that
CAF01 has the ability to generate potent CMI responses
(fig. 1C). As there is accumulating evidence that CMI responses
correlates to protection against influenza [38], there is a need to
expand and optimize ferret specific reagents. Some recent progress
have been made in this area, including the development of an
IFN-c ELISPOT assay [39] as well as flow cytometry assays
[39,40]. These will allow for a deeper investigation of the
importance of the CMI response in providing cross-protection
and long-lived immunity.
In the present study we used the overall level of infection driven
lymphocyte activation by stimulating PBMCs with a polyclonal
activator (PMA and ionomycin) known to expand preferentially
activated T cells in a TCR-independent manner [33,34]. Virus-
specific lymphocytes make up for the largest part of the new
lymphocytes appearing during acute infections [32]. Hence it is
here assumed that the increase in IFN-c producing lymphocytes
after challenge reflects increased numbers of influenza-specific T-
Figure 4. Challenge with A/Brisbane/59/2007 (H1N1) after immunizations with different doses. 6 to 10 months-old ferrets were
immunized twice at two week-intervals with CAF01 adjuvanted and non-adjuvanted influenza vaccine at different dose levels. A third group was left
un-vaccinated. All ferrets were challenged with 107 TCID50 of A/Brisbane/59/2007 (H1N1) four weeks after the second immunization (n = 4). A, B and
C show the relative amounts of viral RNA found in nasal washes of individual infected animals at peak replication day (day 4), measured by
quantitative RT-PCR. D, E and F show hemagglutination inhibition assay serum titers at day 11 using influenza A/Brisbane/59/2007. Values marked
with an asterisk are significantly different (*, p,0.05; **, p,0.01; ***, p,0.001), assessed by ANOVA.
doi:10.1371/journal.pone.0022891.g004
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cells as a consequence of progressive viral infection. Given the
importance of NK cells in controlling the virus during the early
days of the infection [41,42], it is also possible that a significant
part of these IFN- c producing lymphocytes might be NK cells.
The non-vaccinated group and the group that received the vaccine
were both characterized by a higher percentage of IFN-c
producing cells during the later stages of infection than the group
receiving the vaccine adjuvanted with CAF01 (fig. 2E). The
absence of this population of IFN-c producing cells during
infection in ferrets vaccinated with CAF01/influenza vaccine
suggests that the immunity conferred by influenza-specific
antibodies maintained the infection at low levels.
Most influenza vaccination studies in ferrets use parameters
such as weight loss and temperature to evaluate the protection
conferred by vaccines. Clinical scores rely on the similarity in
symptoms, severity and course of the disease between humans and
the ferret model to assess the clinical potential of vaccines.
However, it has been observed in ferrets that different H1N1
strains of influenza induce fever and other constitutional effects
with different severity [43]. As A/New Caledonia/20/99 (H1N1)
and A/Brisbane/59/2007 (H1N1) produce only a mild disease in
ferrets and humans, it was not possible to use differences in weight
loss as an indicator of protection. Similarly, rectal temperature
measurements were inconclusive and the method has been
criticized in several reports [44,45], and subcutaneous chips for
continuous monitoring of the temperature is probably necessary if
this parameter is to be employed in the ferret model [46]. In the
present study it was chosen to focus on viral excretion and the
ability to inhibit viral growth as the most reliable indicators of
protection.
A major finding of these experiments was the dose-sparing effect
of CAF01 on the commercial split-vaccine (fig. 4). Animals that
received 0.15 mg TIV vaccine adjuvanted with CAF01 had higher
antibody titers and controlled viral replication as efficiently as
animals vaccinated with 15 mg of the non-adjuvanted vaccine. It is
interesting to note in this experiment that there is no strict
correlation between the improvement of the antibody response
induced by the vaccine and the reduction of the viral load in
challenged animals. Animals that received CAF01 with 0.15 mg of
the vaccine had IgG, IgA and HAI titers at the same overall level
as animals that received 15 mg of the vaccine with CAF01, yet the
latter displayed lower viral load in their nasal cavities (fig. 4).
Finally, in a head-to-head comparison with a squalene emulsion
with a composition similar to the adjuvant in the Prepandrix
vaccine, CAF01 adjuvanted TIV proved to be both more
immunogenic (fig. 5) and better at reducing the excretion of viral
RNA in infected animals (fig. 5C).
The mechanism by which CAF01 improves the efficacy of the
commercial inactivated influenza vaccines still needs to be
analysed in more detail. Evidence from in vivo and in vitro systems
suggests that the mechanism relies on the fine-tuned combination
of an efficient delivery system (DDA) [47] and the potent
immunomodulator (TDB) [24]. DDA also forms a depot at the
injection site which is important for obtaining long-lived memory
Figure 5. Vaccine-specific IgG antibodies after immunizations
with different TIV formulations. 6 to 10 months-old ferrets were
immunized twice at four week-intervals with different doses of CAF01
adjuvanted, squalene emulsion adjuvanted, and non-adjuvanted
influenza vaccine Vaxigrip season 2008/2009. A. vaccine-specific IgG
titers measured in serum by ELISA two weeks after the first
immunization. B. vaccine-specific IgG titers measured in serum by
ELISA two weeks after the second immunization. All ELISA values are
expressed as geometric mean titers (GMT) and values marked with an
asterisk are significantly different (*, p,0.05; **, p,0.01; ***, p,0.001),
assessed by ANOVA. C. Relative amounts of viral RNA in nasal washes
day 4 after challenge of ferrets immunized with different TIV
formulations: TIV + CAF01 (m), squalene + TIV (N), TIV alone (&) or
mock-vaccinated (.). All ferrets were challenged with 107 TCID50 of A/
Brisbane/59/2007 (H1N1). (*, p,0.05; **, p,0.01; ***, p,0.001).
doi:10.1371/journal.pone.0022891.g005
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responses [48]. In a recent mouse study, CAF01 was found to
induce robust CMI responses maintained for more than one year
[49]. TDB is a synthetic immunomodulator signalling through the
Syk-Card9 pathway and inducing robust combined Th1 and Th17
responses [50]. As a recent study suggest that subsets of IL-17
producing T-cells might have an important role in the immune
response to influenza virus [51], this distinct characteristic of
CAF01 could be highly relevant in an influenza vaccine. Due to a
lack of reagents, it is not possible to investigate the role of Th17
responses in the ferret model.
The observation that CAF01 induces a strong dose-sparing
effect, including long-lived and combined humoral and cellular
responses, warrants further investigation of the potential of CAF01
as adjuvant in influenza vaccines.
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